Castration-resistant prostate cancer (CRPC) is the most common cause of death in men. The effectiveness of HDAC inhibitors has been demonstrated by preclinical models, but not in clinical studies, probably due to the ineffectively accumulation of HDACI in prostate cancer cells. The purpose of this work was to evaluate effects of a novel HDACI (CN133) on CRPC xenograft model and 22Rv1 cells, and develops methods, PET/CT imaging, to detect the therapeutic effects of CN133 on this cancer.
We designed and performed study to compare the effects of CN133 with SAHA on the 22Rv1 xenograft model and 22Rv1 cells. Using PET/CT imaging with [11C] Martinostat and [18F] FDG, we imaged mice bearing 22Rv1 xenografts before and after 21-day treatment with placebo and CN133 (1 mg/kg), and uptake on pre-treatment and post-treatment imaging was measured. The anti-tumor mechanisms of CN133 were investigated by qPCR, western blot, and ChIP-qPCR.
Our data showed that the CN133 treatment led to a 50% reduction of tumor volume compared to the placebo that was more efficacious than SAHA treatment in this preclinical model. [11C] Martinostat PET imaging could identify early lesions of prostate cancer and can also be used to monitor the therapeutic effect of CN133 in CRPC. Using pharmacological approaches, we demonstrated that effects of CN133 showed almost 100-fold efficacy than SAHA treatment in the experiment of cell proliferation, invasion, and migration. The anti-tumor mechanisms of CN133 were due to the inhibition of AR signaling pathway activity by decreased HDAC 2 and 3 protein expressions.
Taken together, these studies provide not only a novel epigenetic approach for prostate cancer therapy but also offering a potential tool, [11C] Martinostat PET/CT imaging, to detect the early phase of prostate cancer and monitor therapeutic effect of CN133. These results will likely lead to human trials in the future.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
castration-resistance prostate cancer
histone deacetylase inhibitors
suberoylanilide hydroxamic acid
positron emission tomography
prostate specific antigen
recombinant Kallikrein 2
transmembrane protease serine 2
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014, (in eng). CA Cancer J Clin. 2014;64(1):9–29.
Torre LA, Sauer AM, Chen MS Jr, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: converging incidence in males and females, (in eng). CA Cancer J Clin. 2016;66(3):182–202.
Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer, (in eng). Semin Oncol. 2013;40(3):244–58.
Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer, (in eng). Prostate. 2004;59(2):177–89.
Weichert W, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy, (in eng). Br J Cancer. 2008;98(3):604–10.
Rathkopf DE, et al. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer, (in eng). Cancer Chemother Pharmacol. 2013;72(3):537–44.
Molife LR, et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC), (in eng). Ann Oncol. 2010;21(1):109–13.
Bradley D, et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium, (in eng). Cancer. 2009;115(23):5541–9.
Liu Y, et al. A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer, (in eng). J Nucl Med. 2013;54(12):2132–8.
Huang CW, Li Z, Cai H, Chen K, Shahinian T, Conti PS. Design, synthesis and validation of integrin alpha2beta1-targeted probe for microPET imaging of prostate cancer, (in eng). Eur J Nucl Med Mol Imaging. 2011;38(7):1313–22.
Gilbert TM, et al. Neuroepigenetic signatures of age and sex in the living human brain. Nat Commun. 2019;10(1):2945.
Gilbert TM, et al. PET neuroimaging reveals histone deacetylase dysregulation in schizophrenia. J Clin Invest. 2019;129(1):364–72.
Wey HY, et al. Insights into neuroepigenetics through human histone deacetylase PET imaging. Sci Transl Med. 2016;8(351):351ra106.
Vaisanen S, Dunlop TW, Sinkkonen L, Frank C, Carlberg C. Spatio-temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1alpha,25-Dihydroxyvitamin D3. J Mol Biol. 2005;350(1):65–77.
Li X, et al. Class I HDAC inhibitors display different antitumor mechanism in leukemia and prostatic cancer cells depending on their p53 status, (in eng). J Med Chem. 2018;61(6):2589–603.
Hu WY, et al. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75. Prostate. 2019;79(10):1166–79.
Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer, (in eng). Pharmacol Ther. 2013;140(3):223–38.
Oh ET, et al. Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells, (in eng). Investig New Drugs. 2012;30(2):435–42.
Denmeade SR, Isaacs JT. A history of prostate cancer treatment, (in eng). Nat Rev Cancer. 2002;2(5):389–96.
Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941, (in eng). J Urol. 2002;168(1):9–12.
Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403(6765):41–5.
Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769–84.
Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed, (in eng). Future Med Chem. 2012;4(4):505–24.
McLeod AB, Stice JP, Wardell SE, Alley HM, Chang CY, McDonnell DP. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer, (in eng). Prostate. 2018;78(4):266–77.
Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose, (in eng). J Urol. 1996;155(3):994–8.
Oyama N, et al. The increased accumulation of [18F] fluorodeoxyglucose in untreated prostate cancer, (in eng). Jpn J Clin Oncol. 1999;29(12):623–9.
Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose, (in eng). Radiology. 1996;199(3):751–6.
Park SE, et al. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer. Investig New Drugs. 2018;36(2):195–205.
Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005;307(5707):269–73.
West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment, (in eng). J Clin Invest. 2014;124(1):30–9.
Munster PN, et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker, (in eng). Br J Cancer. 2009;101(7):1044–50.
Wheler JJ, et al. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers, (in eng). Cancer Chemother Pharmacol. 2014;73(3):495–501.
Jang YG, Hwang KA, Choi KC. Rosmarinic acid, a component of rosemary tea, induced the cell cycle arrest and apoptosis through modulation of HDAC2 expression in prostate cancer cell lines, (in eng). Nutrients. 2018;10(11):1784.
Meek DW. Tumour suppression by p53: a role for the DNA damage response?, (in eng). Nat Rev Cancer. 2009;9(10):714–23.
Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes, (in eng). Nat Rev Mol Cell Biol. 2008;9(5):402–12.
el-Deiry WS, et al. WAF1, a potential mediator of p53 tumor suppression, (in eng). Cell. 1993;75(4):817–25.
This work was supported by a pilot funding from the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital (C.W.), and a short-term visiting program of Sichuan University (Z.C.). The authors are grateful to the Athinoula A. Martinos Center Radiopharmacy Lab staff for the assistant in radiochemistry. The authors thank Drs. Jianzhong Ai, Kunjie Wang and Liang Zhou for their helpful discussion during the paper preparation and revision.
Dr. Changing Wang is a co-inventor of CN133 and [11C] Martinostat used in the paper. The other authors declare that they have no conflict of interest.
The animal study was reviewed and approved by IACUC committee at Massachusetts General Hospital.
Consent for publication
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Oncology - General
Electronic supplementary material
About this article
Cite this article
Chen, Z., Wang, X., Yang, X. et al. Imaging assisted evaluation of antitumor efficacy of a new histone deacetylase inhibitor in the castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 48, 53–66 (2021). https://doi.org/10.1007/s00259-020-04896-7